Broadcast Date: Wednesday, October 30, 2024
Time: 8:00 am PT, 11:00 am ET, 16:00 CET
Artificial Intelligence (AI) and machine learning are transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. Leveraging the rise of large datasets and massive compute power, AI appears poised to expedite and, in some cases, reimagine the design of novel and more effective therapeutics, from cell and gene therapy, oncology, neuroscience, and more.
In GEN’s inaugural virtual summit, The State of AI in Drug Discovery, we proudly host an outstanding group of thought-leaders, researchers and AI entrepreneurs across industry and academia to showcase the latest advances, challenges and concerns regarding the deployment of AI in biotech, with particular emphasis on disrupting the drug discovery process. This exciting event brings together founders and executives from many of the most exciting companies powering the AI revolution, including Recursion, 1910 Genetics, Profluent, Terray Therapeutics, Generate:Biomedicines, and more!
Please join us on October 30th for a dynamic program featuring:
- A keynote presentation with protein design expert David Baker, PhD (University of Washington/HHMI)
- A keynote fireside chat with Najat Khan, PhD (Recursion) on growing the AI in drug discovery industry
- From computational platforms to protein design with Ava Amini, PhD (Microsoft Research), Gevorg Grigoryan, PhD (Generate: Biomedicines), Karen Akinsanya, PhD (Schrödinger)
- Foundational models to read and write the language of biology with Ali Madani, PhD (Profluent), Brian Hie, PhD (Arc Institute), and Alex Rives, PhD (EvolutionaryScale)
- Key considerations for AI-based small molecule drug discovery with experts from 1910 Genetics, Terray Therapeutics, insitro, and Insilico Medicine
- AI in drug discovery’s evolving business landscape with Simon Barnett (Dimension), Sabrina Yang, PhD (Empress Therapeutics/Flagship Pioneering) and Colin Hill (Aitia Bio)
- Breakout sessions from our event sponsors
Registration for The State of AI in Drug Discovery is entirely free.
Guest Speakers Include


Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE